Use of delta5-androstene-3beta ol-7,17-dione in the treatment of lupus erythematosus
OwnerHenry A. Lardy, Charles E. Weeksinventors
Life of this patent
Estimating the term…
Abstract
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3β-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Claims21
A treatment method comprising treating a patient in need of such treatment with an effective autoimmune disorder ameliorative amount of a steroid selected from Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof incapable of being appreciably metabolized to androgens, estrogens or dehydroepiandrosterone.
A treatment method comprising administering an effective preventative amount of a steroid selected from Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof incapable of being appreciably metabolized to androgens, estrogens or dehydroepiandrosterone, to an animal susceptible to lupus erythematosus.
A treatment method comprising treating a patient in need of such treatment with an effective autoimmune disorder curative amount of a steroid selected from Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof incapable of being appreciably metabolized to androgens, estrogens or dehydroepiandrosterone.
Dependencies are inferred from the claim text.